| 11.43 0.15 (1.33%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.5 | 1-year : | 16.94 |
| Resists | First : | 12.42 | Second : | 14.5 |
| Pivot price | 10.7  |
|||
| Supports | First : | 9.91 | Second : | 8.36 |
| MAs | MA(5) : | 11.52  |
MA(20) : | 10.28 |
| MA(100) : | 9.92 |
MA(250) : | 7.46 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 78.2 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 12.42 | Low : | 4.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ THRD ] has closed below upper band by 33.6%. Bollinger Bands are 92.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.62 - 11.69 | 11.69 - 11.75 |
| Low: | 10.79 - 10.88 | 10.88 - 10.95 |
| Close: | 11.31 - 11.43 | 11.43 - 11.54 |
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Mon, 15 Apr 2024
Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares - Yahoo Finance
Mon, 15 Apr 2024
Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares - GuruFocus.com
Mon, 15 Apr 2024
Third Harmonic Bio CEO sells shares worth over $165k - Investing.com India
Sat, 06 Apr 2024
Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation - Simply Wall St
Mon, 01 Apr 2024
Third Harmonic Bio (NASDAQ:THRD) Soars 109% YTD; Is It a Solid Bet for Growth Investors? - TipRanks.com - TipRanks
Tue, 26 Mar 2024
Recap: Third Harmonic Bio Q4 Earnings - Third Harmonic Bio (NASDAQ:THRD) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 93.3 (%) |
| Shares Short | 683 (K) |
| Shares Short P.Month | 1,480 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -9.6 % |
| Return on Equity (ttm) | -11.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -14.66 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|